



Tercica Provides Increlex Launch and Safety Updates

BRISBANE, Calif., Jun 26, 2006 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA)

-- Cumulative Increlex prescriptions more than doubled in the past three months; average number of weekly new prescriptions accelerates

-- Favorable hypoglycemia profile observed in first six months of commercial use, and in recent safety analysis

Tercica, Inc. (Nasdaq:TRCA) today provided an update on the first six months of the Increlex(TM) (mecasermin (rDNA origin) injection) launch in severe primary insulin-like growth factor-1 deficiency (severe Primary IGFD).

At the end of the second three months (June 23, 2006), compared to the end of the first three months (March 28, 2006), cumulative Increlex prescriptions more than doubled (from 61 to 151; a 148% increase). The average weekly new prescriptions in the second three months compared to the first three months increased by 47% (from 4.9 to 7.2 prescriptions per week). Also, at the end of the second three months, 251 additional patients had been identified by pediatric endocrinologists as candidates for Increlex treatment but had not yet been evaluated. This compared to 170 candidates at the end of the first three month period, representing an increase of 48%. Increlex also continues to receive favorable reimbursement response from payers with a reimbursement rate of more than 75% to date. In addition, Increlex was recently added to its first major national managed care Specialty Pharmacy Preferred Drug List.

"We are very encouraged by the accelerating prescription trends seen for Increlex during the most recent three months. Coupled with excellent reimbursement approval rates it is clear that Increlex treatment for children with severe Primary IGFD continues to gain momentum," said John A. Scarlett, M.D., president and chief executive officer of Tercica.

The company also provided an update on the hypoglycemic safety experience in patients treated with commercially available Increlex. During the first six months after launch, three spontaneous reports of hypoglycemia in patients treated with Increlex were received. Two cases were non-serious, and the events resolved either spontaneously or after a snack. Both patients continued on Increlex. In a third case, which was classified as serious, the hypoglycemia persisted for several weeks after Increlex was stopped, suggesting the hypoglycemia was related to the patient's the underlying condition. The patient subsequently resumed Increlex treatment.

An additional analysis of hypoglycemic safety was also provided by Tercica. In 22 patients with severe Primary IGFD, up to four times daily blood glucose measurements were made before and for up to seven days after initiation of Increlex treatment. The results showed no statistically significant difference in the frequency of hypoglycemia observed before versus after the start of Increlex (7.0% and 8.8%, respectively; $p=0.48$).

Thorsten von Stein, M.D., Ph.D., senior vice president and chief medical officer, stated, "This analysis suggests that in children with severe Primary IGFD, hypoglycemia seen during therapy is frequently due to the underlying condition."

About Tercica and Increlex

Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company's first product, Increlex, or recombinant human insulin-like growth factor-1 (rhIGF-1) is approved by the FDA for the long-term treatment of severe Primary IGFD. For further information on Tercica, please visit www.tercica.com.

IGF-1 is the principal hormone necessary for statural growth, and is released in response to stimulation by growth hormone. Primary IGFD is diagnosed in children who have normal or elevated secretion of endogenous growth hormone yet are resistant to its effects, and whose height and serum IGF-1 levels are more than two standard deviations below normal. A sub-set of these children, whose height and serum IGF-1 levels are more than three standard deviations below normal, are diagnosed with severe Primary IGFD.

SOURCE: Tercica, Inc.

Tercica, Inc.

Ina McGuinness, 650-624-4949 (Investors)
VP, Corp. Communications & Investor Relations
ina.mcguinness@tercica.com
Kathleen Rinehart, 650-624-4948 (Media)
Director, Public Relations
kathleen.rinehart@tercica.com

Copyright Business Wire 2006

News Provided by COMTEX